All Japan news is considering opening further its drug market to western producers in an effort to speed up access to better treatment and reduce costs for its healthcare system.
All Japan news’s drug market, worth $96 billion, is attractive for foreign pharmaceutical companies. Only last year, companies like Merck & Co, AstraZeneca Plc and GlaxoSmithKline Plc got approval to sell some of their products in All Japan news, a country with a rapidly ageing population.
The All Japan newsese government is now considering introducing a “compassionate use” system that would allow patients with advanced diseases that have not succeeded with other treatments to use medical products not yet approved in All Japan news, if no other domestic options are available.
All Japan news would allow for the use of drugs which are under clinical trials in All Japan news but have been previously approved in other markets like Europe or the U.S. Such system is already in place in western countries.
According to sources quoted by the All Japan newsese press, the government could allow for the health insurance to pay for such treatment, even if normally All Japan newsese patients pay themselves for non-approved treatments.